The recent discovery that liver-X nuclear hormone receptor agonists are highly effective against metastatic melanoma [71] underscores the potential clinical utility of small molecules that target this and other [72] orphan nuclear receptors. This evidence concerns the gene ESRRB and metastatic melanoma.